Von Rickenbach

“Many small biopharmaceutical companies have successfully raised capital and are now deploying those funds,

Biotech cash to be a boon for CROs, Parexel says

By Zachary Brennan

As small and medium sized biopharma companies continue to raise cash through IPOs and elsewhere, CROs will see an uptick in outsourced work, Parexel founder, chairman and CEO Joseph von Rickenbach predicted in the company’s earnings call last week.

Parexel CEO: Growth Rate Slowing to Manageable Pace

Dispatches from DIA 2013

Parexel CEO: Growth Rate Slowing to Manageable Pace

By Zachary Brennan

Parexel’s growth rate has slowed recently to a pace that the company can more easily keep up with than in years past, CEO Josef von Rickenbach told us at DIA’s annual meeting in Boston on Monday. 

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers